Abstract:Background: Macrophages engineered with chimeric antigen receptors (CAR) are suitable for immunotherapy based on their immunomodulatory activity and ability to infiltrate solid tumours. However, the production and application of genetically edited, highly effective, and mass-produced CAR-modified macrophages (CAR-Ms) are challenging. Methods: Here, we used homology-independent targeted insertion (HITI) for site-directed CAR integration into the safe-harbour region of human pluripotent stem cells (hPSCs). This approach, together with a simple differentiation protocol, produced stable and highly effective CAR-Ms without heterogeneity. Findings: These engineered cells phagocytosed cancer cells, leading to significant inhibition of cancer-cell proliferation in vitro and in vivo. Furthermore, the engineered CARs, which incorporated a combination of CD3ζ and Megf10 (referred to as FRP5Mζ), markedly enhanced the antitumour effect of CAR-Ms by promoting M1, but not M2, polarisation. FRP5Mζ promoted M1 polarisation via nuclear factor kappa B (NF-κB), ERK, and STAT1 signalling, and concurrently inhibited STAT3 signalling even under M2 conditions. These features of CAR-Ms modulated the tumour microenvironment by activating inflammatory signalling, inducing M1 polarisation of bystander non-CAR macrophages, and enhancing the infiltration of T cells in cancer spheroids. Interpretation: Our findings suggest that CAR-Ms have promise as immunotherapeutics. In conclusion, the guided insertion of CAR containing CD3ζ and Megf10 domains is an effective strategy for the immunotherapy of solid tumours. Funding: This work was supported by KRIBB Research Initiative Program Grant (KGM4562431, KGM5282423) and a Korean Fund for Regenerative Medicine (KFRM) grant funded by the Korean government (Ministry of Science and ICT,Ministry of Health and Welfare) (22A0304L1-01).

Engineering M1 macrophages with targeting aptamers for enhanced adoptive immunotherapy by modifying the cell surface

A Chimera Antigen Receptor Containing TLR4 Signaling Domain Enhances CAR-iMACs Polarization and Potency against Solid Tumors

Engineering Macrophages for Cancer Immunotherapy and Drug Delivery

Polyvalent Spherical Aptamer Engineered Macrophages: X-ray-actuated Phenotypic Transformation for Tumor Immunotherapy

Genetically engineered macrophages as living cell drug carriers for targeted cancer therapy

Engineering Macrophages <i>via</i> Nanotechnology and Genetic Manipulation for Cancer Therapy

Human chimeric antigen receptor macrophages for cancer immunotherapy

Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy

Engineering macrophages and their derivatives: A new hope for antitumor therapy

Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy

Advances in Engineered Macrophages: A New Frontier in Cancer Immunotherapy

Macrophage manufacturing and engineering with 5'-Cap1 and N1-methylpseudouridine-modified mRNA

Homology-independent targeted insertion-mediated derivation of M1-biased macrophages harbouring Megf10 and CD3ζ from human pluripotent stem cells

Copper Sulfide Nanoparticle‐Redirected Macrophages for Adoptive Transfer Therapy of Melanoma

A second-generation M1-polarized CAR macrophage with antitumor efficacy

Engineering CpG‐ASO‐Pt‐loaded Macrophages (CAP@M) For Synergistic Chemo‐/Gene‐/Immuno‐Therapy

An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses

The promising role of tumor-associated macrophages in the treatment of cancer

Surface Molecularly Engineered Mitochondria Conduct Immunophenotype Repolarization of Tumor-Associated Macrophages to Potentiate Cancer Immunotherapy

CAR-macrophage: Breaking new ground in cellular immunotherapy

Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment